Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | TSHR | P16473 | 5/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31704273 | 0.87 | ALDH1A1 (0.59) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL14018762 | 0.87 | SLC2A1 (0.53) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| Trimethylammonium SCHEMBL3792932 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL3125006 | 0.80 | ALDH1A1 (0.58) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL13851327 | 0.80 | CHKA (0.71) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12679051 | 0.78 | ALDH1A1 (1.00) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL76217 | 0.78 | ALDH1A1 (1.00) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL4405018 | 0.78 | ALDH1A1 (0.70) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL29178568 | 0.78 | ALDH1A1 (0.48) | ALDH1A1TSHRMAPK1CYP3A4TDP1 | |
| SCHEMBL10597785 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TSHRMAPK1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483290-A | A kind of method that copper catalyzes and synthesizes beta-ketoester | SHANGHAI INST TECH | 2019-11-22 | — | — | CN | claimed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| CN-110869373-B | Antibiotic resistance disruptors | 伦敦皇家学院 | 2023-03-07 | — | — | CN | disclosed |
| CN-112645891-B | Small molecule compound combined with alpha-synuclein aggregate, preparation method and application thereof | 复旦大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20220220151-A1 | METHOD FOR PREPARING PEPTIDES | SULFOTOOLS GMBH (DE) | 2022-07-14 | — | — | US | disclosed |
| US-11319340-B2 | Method for preparing peptides | SULFOTOOLS GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20200377548-A1 | Method for Preparing Peptides | SULFOTOOLS GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3630779-A1 | ANTIBIOTIC RESISTANCE BREAKERS | Kings College London (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1814851-B1 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2013-06-05 | — | — | EP | disclosed |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO-CELTIQUE S.A. (LU) | 2009-04-23 | — | — | US | disclosed |
| EP-1814851-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040181-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2006-04-20 | — | — | WO | disclosed |
| US-5120843-A | Nervous system disorders | UPJOHN (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0487510-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1992-05-27 | — | — | EP | disclosed |
| EP-0358676-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| EP-0293078-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1988-11-30 | — | — | EP | disclosed |
| WO-1988008424-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1988-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377548-A1 | Method for Preparing Peptides | VIP, DNPEP, PEPD | ALDH1A1 4402/4885TSHR 2493/4885MAPK1 1875/4885 |
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | ALDH1A1 481/4885TSHR 1210/4885MAPK1 1621/4885 |
| US-11319340-B2 | Method for preparing peptides | VIP, DNPEP, PEPD | ALDH1A1 4402/4885TSHR 2493/4885MAPK1 1875/4885 |
| US-20220220151-A1 | METHOD FOR PREPARING PEPTIDES | VIP, DNPEP, PEPD | ALDH1A1 4556/4885TSHR 2118/4885MAPK1 1721/4885 |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | CACNA1A, CACNA1E, CACNA1B | ALDH1A1 2001/4885TSHR 2791/4885MAPK1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.